# Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis

> **NCT01511263** · PHASE2 · TERMINATED · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 86 (actual)

## Conditions studied

- Primary Amyloidosis of Light Chain Type

## Interventions

- **DRUG:** Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)
- **DRUG:** Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG

## Key facts

- **NCT ID:** NCT01511263
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01511263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01511263, "Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01511263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*